Journal
TRANSPLANTATION PROCEEDINGS
Volume 42, Issue 8, Pages 3309-3311Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2010.07.034
Keywords
-
Categories
Ask authors/readers for more resources
Wilms' tumor 1 (WT1) is a leukemia associated antigen (LAA) differentially expressed by leukemic blasts. Thus, WT1 may constitute a target for therapies such as those mediated by adoptive-specific T lymphocytes. Serological and cellular immune responses have been elicited by WT1 in patients with leukemia. Specific CD8(+) T cells able to recognize this antigen can be selected by streptamers and then infused into leukemia patients. Potentially, these T cells could lyse leukemic blasts expressing WT1. The only good manufacturing practice-certified technology is streptamers, which are available for antigen-specific T-cell sorting. Immunocompromised patients may have their antigen-specific immune responses restored through the transfer of adoptive T cells specific for this LAA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available